These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 21712498

  • 1. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.
    Samineni D, Desai PB, Sallans L, Fichtenbaum CJ.
    J Clin Pharmacol; 2012 Jun; 52(6):922-31. PubMed ID: 21712498
    [Abstract] [Full Text] [Related]

  • 2. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.
    Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW.
    J Acquir Immune Defic Syndr; 2008 Apr 15; 47(5):570-8. PubMed ID: 18176327
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
    Li Y, Jiang X, Lan K, Zhang R, Li X, Jiang Q.
    Clin Ther; 2007 Oct 15; 29(10):2194-203. PubMed ID: 18042475
    [Abstract] [Full Text] [Related]

  • 4. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
    Busti AJ, Bain AM, Hall RG, Bedimo RG, Leff RD, Meek C, Mehvar R.
    J Cardiovasc Pharmacol; 2008 Jun 15; 51(6):605-10. PubMed ID: 18520949
    [Abstract] [Full Text] [Related]

  • 5. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
    Martin PD, Warwick MJ, Dane AL, Brindley C, Short T.
    Clin Ther; 2003 Oct 15; 25(10):2553-63. PubMed ID: 14667956
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
    Custodio JM, Wang H, Hao J, Lepist EI, Ray AS, Andrews J, Ling KH, Cheng A, Kearney BP, Ramanathan S.
    J Clin Pharmacol; 2014 Jun 15; 54(6):649-56. PubMed ID: 24375014
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
    McKenney JM.
    Am J Health Syst Pharm; 2005 May 15; 62(10):1033-47. PubMed ID: 15901588
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
    Kakuda TN, Opsomer M, Timmers M, Iterbeke K, Van De Casteele T, Hillewaert V, Petrovic R, Hoetelmans RM.
    J Clin Pharmacol; 2014 Aug 15; 54(8):949-57. PubMed ID: 24644095
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
    Li XN, Xu HR, Chen WL, Chu NN, Zhu JR.
    Clin Ther; 2010 Mar 15; 32(3):575-87. PubMed ID: 20399994
    [Abstract] [Full Text] [Related]

  • 10. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F, Lefebvre E, Sekar V, Van Baelen B, Vangeneugden T, Vandevoorde A, Diego Miralles G.
    HIV Med; 2009 May 15; 10(5):318-27. PubMed ID: 19210693
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
    Schöller-Gyüre M, Kakuda TN, Sekar V, Woodfall B, De Smedt G, Lefebvre E, Peeters M, Hoetelmans RM.
    Antivir Ther; 2007 May 15; 12(5):789-96. PubMed ID: 17713162
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K, Hanna I, Meyers D, Salunke A, Movva A, Majumdar T, Natrillo A, Vapurcuyan A, Rebello S, Sunkara G, Chen J.
    Int J Clin Pharmacol Ther; 2015 May 15; 53(5):345-55. PubMed ID: 25740267
    [Abstract] [Full Text] [Related]

  • 13. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
    Martin PD, Dane AL, Schneck DW, Warwick MJ.
    Clin Ther; 2003 Feb 15; 25(2):459-71. PubMed ID: 12749507
    [Abstract] [Full Text] [Related]

  • 14. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
    Martin PD, Warwick MJ, Dane AL, Cantarini MV.
    Clin Ther; 2003 Aug 15; 25(8):2215-24. PubMed ID: 14512129
    [Abstract] [Full Text] [Related]

  • 15. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
    Derks M, Abt M, Phelan M, Turnbull L, Meneses-Lorente G, Bech N, White AM, Parr G.
    J Clin Pharmacol; 2010 Oct 15; 50(10):1188-201. PubMed ID: 20489031
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
    van der Lee M, Sankatsing R, Schippers E, Vogel M, Fätkenheuer G, van der Ven A, Kroon F, Rockstroh J, Wyen C, Bäumer A, de Groot E, Koopmans P, Stroes E, Reiss P, Burger D.
    Antivir Ther; 2007 Oct 15; 12(7):1127-32. PubMed ID: 18018771
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
    Martin PD, Mitchell PD, Schneck DW.
    Br J Clin Pharmacol; 2002 Nov 15; 54(5):472-7. PubMed ID: 12445025
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.